Symposium SKiN-HUID "Progress in Personalised Medicine Developing a novel biopharmaceutical, from bench to production" - 16 May 2019
A major challenge in the development of biopharmaceuticals is achieving clinical grade products for clinical evaluation. Under the framework of the Interreg V Netherlands and Flanders -project SkiN-HUID, Basic Pharma and MosaMedix, Universities of Maastricht, Antwerp and the Flemish Institute for Biotechnology (VIB) at the KU Leuven joined forces. SKiN-HUID develops a novel treatment of skin cancer that combines administration of a biopharmaceutical medicine targeting cancer cells and application of electrical and hyperthermal stimulation of the cancer that enhances the efficacy of the biopharmaceutical medicine.
Within SKiN-HUID the consortium aims to overcome the major hurdle of bringing a novel biopharmaceutical product to the clinic: the GMP-production of clinical grade biopharmaceutical medicine for the first phase of clinical studies. Basic Pharma set up a novel pilot plant for the GMP-production of biopharmaceutical medicines. This facility forms an essential part of the value chain linking preclinical and clinical evaluation of the efficacy of biopharmaceutical medicines.
Collaboration between University and Industry, access to finance, infrastructure and regulatory insight is paramount in mastering this challenge. We cordially invite you to join our mission in accelerating personalised medicine innovations.
The symposium takes place on 16 May 2019 at the Brightlands Chemelot Campus, Geleen, NL.
The meeting is especially of interest to companies active in biotechnology, pharmaceuticals and medical devices, and start-up support.
Register now for the event free of charge (registration mandatory) via: www.lifeteczone.nl/nl/agenda/mei2019
Click here for the programme of the meeting.